Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 225 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June June 5, 2025 Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in... April 23, 2026 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic... August 16, 2021 FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma August 27, 2024 Load more HOT NEWS Tarlatamab Shows Promise for Some People with Small Cell Lung Cancer FDA Approvals Expand Initial Treatment Options for Multiple Myeloma Breakthrough SARS-CoV-2 Infection Following COVID-19 Vaccination in Patients with Cancer FDA Approves a Fixed-Dose Combination of Nivolumab and Relatlimab for Unresectable...
